Bli medlem
Bli medlem

Du är här


Bavarian Nordic A/S: Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 23 April 2015

KVISTGAARD, Denmark - April 23, 2015
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today held the Annual General
Meeting with the results as follows:

* The Annual Report for 2014 was adopted. The Board of Directors' proposal to
transfer the Company's result to next year was also adopted.
* The General Meeting adopted a resolution to discharge the Board of
Directors and the Board of Management from their obligations.
* Gerard van Odijk, Anders Gersel Pedersen, Claus Bræstrup, Erik G. Hansen
and Peter Kürstein were re-elected to the Board of Directors. The Board of
Directors constituted itself with Gerard van Odijk as Chairman and Anders
Gersel Pedersen as Deputy Chairman.
* Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as
* The proposal to change the Company's shares from being issued to the bearer
to being issued in the name of the holder was adopted
* The proposal for a remuneration policy including changing the general
guidelines for incentive remuneration of the Board of Directors and the
Executive Management was adopted
* The proposal to increase and extend the Board of Directors authorization to
increase the share capital of the Company was adopted.
* The proposal to increase and extend the Board of Directors authorization
for issuing Warrants was adopted.
* The suggested remuneration of the Board of Directors and the Board
Committees for the current financial year was approved.
* The Board of Directors was authorized to let the Company purchase its own


Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43

Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271

About Bavarian Nordic

Bavarian Nordic is a biopharmaceutical company focused on the development and
manufacturing of cancer immunotherapies and vaccines for infectious diseases.
Through a long-standing collaboration with the U.S. Government, Bavarian
Nordic has developed a portfolio of biological countermeasures, including the
non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for
emergency use by the U.S. and other governments. The vaccine is approved in
the EU (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its
partner Janssen are pioneering the development of an Ebola vaccine, which has
been fast-tracked by authorities in response to the current situation in West
Africa. Additionally, in collaboration with the National Cancer Institute,
Bavarian Nordic has developed a portfolio of active cancer immunotherapies
based on its versatile pox-virus based technologies, including PROSTVAC®,
which is currently in Phase 3 clinical development for the treatment of
advanced prostate cancer. The company has partnered with Bristol-Myers Squibb
for the potential commercialization of PROSTVAC. For more information
visitwww.bavarian-nordic.comor follow us on Twitter@bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. We
undertake no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances after the date made,
except as required by law.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.